19:31 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma; colorectal cancer Cell culture and mouse studies suggest MLKL mRNA plus electroporation could help treat melanoma and colorectal cancer. In a mouse melanoma cell line and three human melanoma cell lines, transfection with...
17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies identified a GSDMD inhibitor that could help treat sepsis. In vitro , the previously identified necroptosis inhibitor necrosulfamide bound GSDMD with a K d of 32 μM. In...
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in Nature Neuroscience , identify potential...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Cell culture and mouse studies suggest combining Ridaura auranofin and glutathione synthesis inhibitors with RIPK1 or MLKL inhibitors could help treat tuberous sclerosis complex-associated tumors, which are caused by loss-of-function mutations in the...
21:01 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Hepatic Patient sample and mouse studies suggest inhibiting MLKL could help treat autoimmune hepatitis. In patients with autoimmune hepatitis, liver levels of MLKL were higher than in patients with hepatic steatosis or primary biliary...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3); mixed-lineage kinase domain-like (MLKL)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting the necroptosis-related proteins RIPK1 , RIPK3 or MLKL could help treat atherosclerosis. Levels of RIPK3 and MLKL were higher in carotid plaque samples from...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL)

Renal disease INDICATION: Renal damage Cell and mouse studies suggest inhibiting RIPK3 or MLKL could help treat crystal-induced acute kidney injury (AKI). In mouse kidney epithelial cells, siRNA targeting RIPK3 or MLKL decreased cell death...